CoChat

Clinical efficacy of buprenorphine: comparisons to methadone and placebo

LING, W · 2003 · Drug and Alcohol Dependence

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Buprenorphine has been studied extensively since 1978 when it was initially proposed as an alternative to methadone for treatment of opioid dependence. Early work by Jasinski et al., 1978; Mello and Mendelson, 1980; Mello et al., 1982; Mello et al., 1983 and Mendelson et al., 1984 and their colleagues demonstrated buprenorphine's low physical abuse potential and its ability to substitute for heroin and reduce heroin self-administration in opiate-dependent humans. The subsequent early clinical studies suggested that, in clinical settings, buprenorphine was a safe and efficacious opiate dependence pharmacotherapy. Formal approval for general clinical use, however, required that systematic data be gathered on buprenorphine's safety and efficacy in larger groups and a series of controlled clinical trials was designed to evaluate its utility from a medication development perspective. In general, these trials adhered to one of three basic protocol designs: comparison of buprenorphine to methadone; dose comparisons using dose response as an indicator of efficacy; and comparison of buprenorphine to placebo. Retention in treatment, reduction in illicit drug use and craving, and patient and staff ratings of improvements were the most frequently used outcome indicators in these trials. Additional data collected included optimum dosing and dosage schedules, adverse reactions and common side-effects, and other information intended to clarify buprenorphine's benefit-risk relationship and to help prepare guidelines for its safe marketing and utilization by physicians in general clinical practice. This paper presents a review of the buprenorphine/methadone comparison trials conducted in the United States and two such trials conducted in Europe. Also reviewed are three placebo-controlled trials and a buprenorphine/methadone detoxification study. Overall, this series of studies did firmly establish the efficacy of buprenorphine alone and in comparison to methadone.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0376-8716(03)00059-0

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Cited by

See all 125

Metadata

Authors
LING, W.
Affiliations
University of California, Los Angeles (US)
Corresponding author
LING, W
ORCID
LING, W
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2003-05
Volume
70
Issue
2
Pages
S49-S57
ISSN
0376-8716 (ISSN-L)
OpenAlex
W2048376222
Cited by
121
References
18
Citations by year
2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 6 · 2019: 4 · 2018: 3 · 2016: 7 · 2015: 5 · 2014: 6 · 2013: 4 · 2012: 6
FWCI
9.14
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (DA09260, DA99004, P50DA012755, P50DA009260, DA12755)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
buprenorphine, methadone, opioid use disorder, opioid substitution therapy, heroin addiction, treatment retention, illicit drug use, craving, detoxification, dose-response relationship, adverse effects, risk-benefit ratio
MeSH terms
Buprenorphine, Humans, Methadone, Narcotic Antagonists, Opioid-Related Disorders, Placebos, Substance Withdrawal Syndrome, Controlled Clinical Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical efficacy of buprenorphine: comparisons to methadone and placebo. https://app.cochat.ai/papers/10.1016/s0376-8716(03)00059-0
The paper
LING, W. (2003). Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug and Alcohol Dependence. https://doi.org/10.1016/s0376-8716(03)00059-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.